Experts Meeting
Empowering the Potential of ctDNA-MRD
An academic event in Danang, Vietnam, to foster collaboration and knowledge sharing among oncologists in the Asia-Pacific region.
The K-CONNECT Platform creates as a collaborative initiative that brings together leading oncologists and researchers from across the region. The platform serves as a bridge between cutting-edge technology and expert practitioners, aiming to unlock the potential of ctDNA-MRD for precision and personalized oncology.
EXPERTS MEETING
| K-CONNECT APAC 2025
- Da Nang, Vietnam
An exclusive event in Danang, Vietnam, bringing together leading oncologists and researchers from across the AsiaPacific region. K-CONNECT APAC 2025 aims to delve into the cutting-edge applications of ctDNA-MRD, share realworld experiences, and collaborate on pioneering advancements in precision oncology.
The event will feature over 100 invited oncologists as speakers and delegates, hosted by Gene Solutions.
CLINICAL TRIAL SUPPORT
| A COLLABORATIVE EFFORT TO ADVANCE CANCER CARE
The K-CONNECT Platform, in collaboration with local partners and Biopharma companies, offers oncologist access to a complimentary first K-TRACK test, or Applicants for supported diagnostics assays in clinical research. This initiative underscores our commitment to advancing precision oncology and improving patient outcomes.
EXPERIENCE MRD
| LEADING THE FUTURE OF PRECISION ONCOLOGY
Join leading oncologists across Asia in transforming cancer care through cutting-edge ctDNA-MRD technology.
Oncologists can easily access this offer through the K-CONNECT Platform. Simply log in to your account and follow the designated pathway. Our user-friendly interface will guide you through the process, ensuring a seamless experience.
WEBINARS
A series of webinars for knowledge sharing, covering the latest advancements in cancer treatment and emerging technologies in precision medicine.
Online Resources
CASE STUDIES
Source:
JCO Oncology Advances
Cancer type:
Lung Cancer
This is the story of a 60-year-old man with stage IV NSCLC, whose case demonstrates how ctDNA monitoring predicted disease progression ahead of imaging, offering a critical opportunity for earlier intervention.
- To protect patient confidentiality, all names and images mentioned have been changed
Source:
JCO Oncology Advances
Cancer type:
Lung Cancer
The case of a 66-year-old woman with metastatic lung cancer, illustrates how genomic profiling and ctDNA monitoring together provide a sharper, more dynamic view of tumor evolution — even when conventional markers appear to improve.
- To protect patient confidentiality, all names and images mentioned have been changed
Source:
JCO Oncology Advances
Cancer type:
Lung Cancer
The case of a 65-year-old woman with EGFR-mutant illustrates how genomic profiling and ctDNA monitoring work hand-in-hand to guide therapy and track response — well before imaging changes become apparent.
- To protect patient confidentiality, all names and images mentioned have been changed
Source:
JCO Oncology Advances
Cancer type:
Lung Cancer
The story of Rajesh, a 75-year-old man diagnosed with stage IA lung adenocarcinoma, reminds us that while CT scans remain a staple in surveillance, molecular recurrence can emerge well before structural changes are visible.
- To protect patient confidentiality, all names and images mentioned have been changed
Source:
JCO Oncology Advances
Cancer type:
Colorectal Cancer
This real-world case of Long, a 46-year-old man diagnosed with stage III sigmoid colon cancer, illustrates how both approaches informed risk stratification and a tailored adjuvant treatment strategy.
- To protect patient confidentiality, all names and images mentioned have been changed
Source:
JCO Oncology Advances
Cancer type:
Breast Cancer
Meet Maya, a 35-year-old woman diagnosed with HER2-positive breast cancer. Her story highlights the real-world impact of using both technologies to personalize treatment, track progress, and achieve long-term disease control.
- To protect patient confidentiality, all names and images mentioned have been changed
PUBLICATIONS
ctDNA Monitoring to Predict the Efficacy of TNT for Rectal Cancer
Publisher:
clinicaltrials.gov
Publication date:
September 16, 2023
Key finding:
This is a prospective observational study, in collaboration with 3 hospitals (175 Military Hospital, Nguyen Tri Phuong Hospital, and 108 Military Central Hospital), plans to recruit 100 patients with stage II-III rectal cancer and indicated for total neoadjuvant therapy. K-TRACK assay will use to evaluate value of ctDNA in Predict the Efficacy of TNT for Rectal Cancer.
Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer
Publisher:
clinicaltrials.gov
Publication date:
October 18, 2023
Key finding:
This prospective and observational study, in collaboration with University Medical Center HCMC, plans to recruit 75 patients with stage II-III HER+/Triple Negative Breast cancer and indicated for neoadjuvant chemotherapy. K-TRACK assay will use aim to determine the detection rate and change of ctDNA in blood samples of cancer patients before, during and after neoadjuvant treatment.
SPEAKERS & PANELISTS
Associate Professor
National Referral for Repiratory diseases, RSUP Persahabatan
